Galectin Therapeutics Inc (NASDAQ:GALT) — Market Cap & Net Worth
Market Cap & Net Worth: Galectin Therapeutics Inc (GALT)
Galectin Therapeutics Inc (NASDAQ:GALT) has a market capitalization of $316.67 Million ($316.67 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14622 globally and #3468 in its home market, demonstrating a -20.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galectin Therapeutics Inc's stock price $3.68 by its total outstanding shares 100849644 (100.85 Million). Also see GALT asset base for a full breakdown of the balance sheet.
Galectin Therapeutics Inc Market Cap History: 2015 to 2026
Galectin Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $165.39 Million to $371.13 Million (1.89% CAGR). Also see how efficiently does Galectin Therapeutics Inc generate cash for how efficiently the company converts equity into cash flow.
Index Memberships
Galectin Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #399 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1423 of 3165 |
Weight: Galectin Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Galectin Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galectin Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GALT share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GALT by Market Capitalization
Companies near Galectin Therapeutics Inc in the global market cap rankings as of September 17, 2026. Review GALT goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Galectin Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Galectin Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Galectin Therapeutics Inc's market cap moved from $165.39 Million to $ 371.13 Million, with a yearly change of 1.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $371.13 Million | -11.54% |
| 2025 | $419.53 Million | +222.48% |
| 2024 | $130.10 Million | -22.29% |
| 2023 | $167.41 Million | +46.90% |
| 2022 | $113.96 Million | -45.41% |
| 2021 | $208.76 Million | -7.59% |
| 2020 | $225.90 Million | -21.68% |
| 2019 | $288.43 Million | -16.62% |
| 2018 | $345.91 Million | +2.69% |
| 2017 | $336.84 Million | +240.89% |
| 2016 | $98.81 Million | -40.26% |
| 2015 | $165.39 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Galectin Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $316.67 Million USD |
| MoneyControl | $316.67 Million USD |
| MarketWatch | $316.67 Million USD |
| marketcap.company | $316.67 Million USD |
| Reuters | $316.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhos… Read more